SUMMIT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.86 USD | +8.73% |
|
+10.29% | +47.89% |
| Apr. 11 | Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors | CI |
| Apr. 09 | Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed | RE |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Summit Therap...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.099
GBP
Average target price
6.375
GBP
Spread / Average Target
+105.71%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +47.89% | 2.71B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Transcript : Summit Therapeutics Inc., Q3 2023 Earnings Call, Nov 07, 2023
